<DOC>
	<DOCNO>NCT02128906</DOCNO>
	<brief_summary>The goal clinical research study learn chemotherapy combination may effective treat locally advanced head neck squamous cell carcinoma ( HNSCC ) . The side effect combination also study . This study treatment consist intensity-modulated radiation therapy ( IMRT ) concurrent chemotherapy . For study chemotherapy , patient randomize cisplatin combination docetaxel cetuximab . Subjects stratify depend HPV status presence ERCC-1 [ 4F9 ] tumor prior randomization . The study evaluate cisplatin vs. docetaxel-cetuximab overall population , test radiation chemotherapy combination work best relationship much ERCC-1 [ 4F9 ] express tumor .</brief_summary>
	<brief_title>Radiotherapy With Cisplatin vs. Docetaxel-cetuximab HNSCC : ERCC1 Biomarker Enrichment Interaction Design</brief_title>
	<detailed_description>If randomize cisplatin arm , receive cisplatin , 40 mg/m2 , administer intravenously ( IV ) week ( +/- 2 day ) 7 week . Per investigator discretion , radiation continue beyond 7 week due technical factor ( toxicity delay ) , 8th dose concurrent cisplatin may add . It strongly prefer cisplatin administer Monday , Tuesday , Wednesday treatment week maximize overlap radiation ; administration Thursday Friday logistical purpose note however constitute protocol violation . Cisplatin give either radiation therapy fraction give day . If dose cisplatin omit radiotherapy ongoing , make added end treatment . The omit dose reason omission record site 's source documentation . If radiotherapy hold , cisplatin hold treatment break resume radiation restarts . In case , cisplatin dose consider skip omit , delay . If randomize arm receive cetuximab , 250 mg/m2 , IV 60 minute weekly schedule ( +/- 2 day ) . . Cetuximab may administer either radiation fraction give day . Docetaxel administer least 30 minute follow cetuximab . It permit make missed dos cetuximab docetaxel . If radiation therapy treatment break occur , cetuximab held . When radiation restarts , cetuximab resume . It strongly prefer cetuximab administer Monday , Tuesday , Wednesday treatment week maximize overlap radiation ; administration Thursday Friday logistical purpose note however constitute protocol violation . Cetuximab give week ( +/- 2 day ) total 7 dos concurrent radiation therapy docetaxel .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Pathologically confirm squamous cell carcinoma , undifferentiated carcinoma , poorly differentiate carcinoma oropharynx , larynx , hypopharynx evidence distant metastasis . Biopsy sample primary tumor pathology report document diagnostic tissue type require . Patients must stage III , IVa IVb disease determine image study complete head neck exam . Staging evaluation accordance American Joint Committee Cancer Staging Manual , 7th edition . Patients oropharyngeal squamous cell carcinoma may p16 ( + ) p16 ( ) disease ; patient , p16 status must know prior randomization . Assessment p16 status may occur locally centrally . Note : The definition p16 ( + ) disease diffuse nuclear cytoplasmic staining ≥ 70 % tumor cell . Patients must untreated curativeintent surgery current diagnosis Stage III , IVa , IVb disease . Diagnostic biopsy primary tumor and/or nodal site permit . Diagnostic simple tonsillectomy permit , provide patient RECISTmeasurable residual tumor and/or nodal disease . Patients second HNSCC primary tumor eligible study , provide 2 year elapse since first diagnosis HNSCC , original tumor manage surgery ( adjuvant chemotherapy/radiotherapy ) , recur . Patients simultaneous primary bilateral tumor exclude , exception patient bilateral tonsil cancer patient T12 , N0 , M0 resect differentiate thyroid carcinoma , eligible . No prior systemic treatment ( chemotherapy biologic/molecular target therapy ) radiation treatment head neck cancer . Patients may receive chemotherapy radiation previous , curatively treat nonHNSCC malignancy , provide least 2 year elapse . Patients must untreated radiation clavicle . Patients history curativelytreated nonHNSCC malignancy must diseasefree least 2 year except carcinomainsitu cervix , nonmelanomatous skin cancer , T12 , N0 , M0 resect differentiate thyroid carcinoma . Diagnostic primary tumor tissue must available ERCC1 stain Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 ( See Appendix 8 ) Age ≥ 18 Patients must measurable disease accord RECIST 1.1 Patients must follow laboratory value measure within 14 day registration : Absolute neutrophil count ( ANC ) &gt; 1500/mm3 Hemoglobin ( Hb ) &gt; 8.0 g/dL Platelet count ( PLT ) &gt; 100,000/mm3 Creatinine clearance ≥ 45 ml/min determine 24hour collection estimate CockraftGault formula : Calculated Creatinine Clearance = [ ( 140age ) X ( actual body weight kg ) X ( 0.85 female ) ] / ( 72 X serum creatinine ) Serum bilirubin &lt; 2 mg/dL AST ( aspartate aminotransferase ) ALT ( alanine aminotransferase ) &lt; 3 time upper limit normal ( ULN ) The following assessment require within 14 day prior registration : Na , K , Cl , glucose , Ca , Mg , albumin . The following metabolic value exclude patient study enrollment : Serum calcium ( ionize adjust albumin ) &lt; 7 mg/dl ( 1.75 mmol/L ) &gt; 12.5 mg/dl ( &gt; 3.1 mmol/L ) despite intervention normalize level Magnesium &lt; 0.9 mg/dl ( &lt; 0.4 mmol/L ) &gt; 3 mg/dl ( &gt; 1.23 mmol/L ) despite intervention normalize level Potassium &lt; 3.5 mmol/L &gt; 6 mmol/L despite intervention normalize level Sodium &lt; 130 mmol/L &gt; 155 mmol/L despite intervention normalize level Note : Patients initial magnesium &lt; 0.5 mmol/L ( 1.2 mg/dl ) may receive corrective magnesium supplementation continue receive either prophylactic weekly infusion magnesium and/or oral magnesium supplementation ( eg , magnesium oxide ) investigator 's discretion . No prior severe infusion reaction monoclonal antibody Written inform consent must obtain patient prior begin therapy . Patients ability understand willingness sign write informed consent document . Informed consent must obtain patient prior begin therapy , include consent mandatory tissue submission ERCC1 staining ( p16 stain locally conduct ) . Patients ability understand willingness sign write informed consent document . No unstable angina myocardial infarction within prior 6 month ; symptomatic congestive heart failure ; serious cardiac arrhythmia require medication ; cerebrovascular ischemia stroke within past 6 month . No uncontrolled intercurrent illness include active infection , uncontrolled diabetes , uncontrolled hypertension , uncontrolled psychiatric illness investigator 's opinion would limit compliance study requirement compromise patient safety . Women must pregnant breast feed chemotherapy and/or cetuximab may harmful fetus nursing infant . Pregnant woman exclude study chemotherapy and/or cetuximab potential teratogenic abortifacient effect . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation . Should woman become pregnant suspect pregnant study , inform treat physician immediately . All female childbearing potential must blood test urine study within 14 day registration rule pregnancy . HIVpositive patient receive combination antiretroviral therapy exclude study possible drug interaction study drug . Appropriate study undertake patient receive combination antiretroviral therapy indicate . Note : HIV test require entry protocol . Patients may receive antineoplastic investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ERCC1</keyword>
	<keyword>squamous cell carcinoma</keyword>
	<keyword>oropharynx</keyword>
	<keyword>larynx</keyword>
	<keyword>hypopharynx</keyword>
	<keyword>p16</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cetuximab</keyword>
	<keyword>cisplatin</keyword>
	<keyword>EGFR</keyword>
	<keyword>Biomarker</keyword>
	<keyword>efficacy</keyword>
	<keyword>head neck</keyword>
	<keyword>tongue</keyword>
	<keyword>throat</keyword>
</DOC>